CEL-SCI Stock Forecast for 2023 - 2025 - 2030
Updated on 05/05/2024
CEL-SCI Stock Forecast and Price Target
The average price target for CEL-SCI's stock lately set by several renowned analysts is $7.70, which would result in a potential upside of approximately 372.39% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $8.40 and a low estimate of $7.00. Even if you are not interested in CVM stock, you should still be aware of its competitors.
372.39% Upside
CEL-SCI Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Price for CEL-SCI has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $1.70 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for CEL-SCI will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$163.79 | Buy/Sell | $178.42 | 12.95% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$311.29 | Buy/Sell | $303.65 | 2.80% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$64.78 | Buy/Sell | $87.82 | 23.49% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$217.51 | Buy/Sell | $299.62 | 32.64% |
CEL-SCI Revenue Forecast for 2023 - 2025 - 2030
In the last zero years, CEL-SCI's Revenue has decreased from $560.00k to $560.00k – a 0.00% drop. In the following year, 1 experts forecast that CEL-SCI's Revenue will decrease by 100.00%, to $0.00. In 2030, professionals predict that CEL-SCI's Revenue will decrease by 100.00%, to $0.00.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.44 | Buy/Sell | $111.56 | 33.43% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.76 | Buy/Sell | $77.05 | 46.02% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$76.97 | Buy/Sell | $34.00 | 49.41% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.19 | Buy/Sell | $85.71 | 11.48% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$13.63 | Buy/Sell | $20.42 | 87.09% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.44 | Buy/Sell | $52.00 | 125.04% |
CEL-SCI EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, CEL-SCI's EBITDA has grown, increasing from $-26.83M to $-29.32M – an increase of 9.28%. For next year, the 1 analysts predict EBITDA of $-40.18M, which would mean an increase of 37.04%. Over the next seven years, the pros' prediction is EBITDAof $-30.38M, which would mean a seven-year growth forecast of 3.61%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.40 | Buy/Sell | $17.90 | 92.31% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.05 | Buy/Sell | $33.78 | 75.95% |
CEL-SCI EBIT Forecast for 2023 - 2025 - 2030
CEL-SCI's EBIT has increased by 8.59% In the last three years, going from $-28.99M to $-31.48M. The next year, 2 experts forecast that CEL-SCI's EBIT will decrease by 9.78%, reaching $-28.40M. In 2030, professionals predict that CEL-SCI's EBIT will decrease by 33.29%, reaching $-21.00M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$42.56 | Buy/Sell | $63.29 | 80.92% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.83 | Buy/Sell | $42.58 | 14.99% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$8.72 | Buy/Sell | $9.94 | 60.55% |
CEL-SCI EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, EPS for CEL-SCI has grown by 100.00%, going from $-0.87 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $-0.53 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for CEL-SCI will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.54 | Buy/Sell | $40.00 | 28.84% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.74 | Buy/Sell | $25.00 | 108.69% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.81 | Buy/Sell | $6.00 | 17.47% |
.jpg)